Covington Secures Key Preliminary Injunction for Indivior

WASHINGTON—Covington's patent litigators secured a significant win on behalf of Indivior, obtaining a preliminary injunction preventing Dr. Reddy's Laboratories from launching a generic version of Indivior's SUBOXONE®  Sublingual Film used in treatment of opioid addiction. The court's decision recognizes that Indivior had shown a likelihood of success on the merits and that it would be irreparably harmed in the absence of injunctive relief.

Indivior is a global pharmaceutical company focused on treatment of addiction and its co-occurring disorders, and SUBOXONE® Film currently accounts for the majority of its revenue. After Dr. Reddy's generic launch, obtaining an injunction and protecting Indivior's intellectual property rights were critical to Indivior's business. Indivior is the exclusive licensee of the patent at issue in the injunction, U.S. Patent No. 9,931,305, which issued earlier this year.

The Covington team was led by Jeffrey Elikan and Jeffrey Lerner, and included Jason Fowler, Erica Andersen, Matthew Kudzin, Isaac Belfer, Ashley Kwon, Philip May, Hannah Jiam, and Robert Zhou.